DelveInsight’s Oral Mucositis market report provides an in-depth understanding of the Oral Mucositis, historical and forecasted epidemiology, as well as Oral Mucositis market trends in the 7MM (the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan). The Oral Mucositis market report also covers current treatment practices, emerging drugs, Oral Mucositis market share of individual therapies, as well as current and forecasted Oral Mucositis market size from 2018 to 2030, segmented by seven major markets.
Some of the Important Findings from the Oral Mucositis Market Report
According to Sonis et al., Oral Mucositis prevalence in the general cancer patient population ranges from 30% to 40%.
As per DelveInsight’s Oral Mucositis epidemiology insights, the total incident cases were found to be 1,480,453 in the 7MM in 2020.
According to DelveInsight, the highest number of Oral Mucositis incident cases among the grade-specific was of Grade III, followed by Grade I, II and IV respectively in the United States in 2020.
Key players such as Galera Therapeutics, Monopar Therapeutics, Soligenix, NeoMedLight, BrainCool, MuReva (Lumitex), Oncozenge, and others are involved in developing drugs/devices for Oral Mucositis.
Galera’s lead product candidate Avasopasem, also known as Avasopasem manganese or GC4419, is a highly selective small molecule superoxide dismutase (SOD) mimetic under investigation for the treatment of radiation-induced severe oral mucositis.
SGX942 (Dusquetide) is an investigational agent being developed by Soligenix. SGX942 is a rapid 4-minute infusion given twice a week during chemotherapy and/or radiation treatment to reduce the duration and severity of severe oral mucositis.
MuReva is developing the MuReva Phototherapy System, which is an intraoral illuminated mouthpiece that can deliver light to all soft tissue susceptible to oral mucositis at the same time.
To get a detailed analysis of the WHO oral mucositis grading scale, request sample @ Oral Mucositis Guidelines
The Oral Mucositis market report also discusses current Oral Mucositis treatment practices/algorithms, Oral Mucositis market drivers, Oral Mucositis market barriers, and unmet medical needs in order to curate the best opportunities and assess the market’s underlying potential.
Oral Mucositis: Overview
Oral Mucositis is characterized by erythematous and ulcerative lesions of the oral mucosa in cancer patients receiving chemotherapy and/or radiation therapy to fields involving the oral cavity. This can cause a variety of issues, including pain, nutritional issues due to inability to eat, and an increased risk of infection due to open sores in the mucosa.
Oral Mucositis Epidemiology Segmentation
The Oral Mucositis report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:
Oral Mucositis Total Incident Cases
Oral Mucositis Grade-Specific Incident Cases
Oral Mucositis Total Treated Cases
Oral Mucositis Treatment Landscape
The current clinical management of Oral Mucositis focuses primarily on palliative measures such as pain management, nutritional support, and the maintenance of good oral hygiene. Some of the FDA-approved drugs/devices used for Oral Mucositis treatment include Kepivance (palifermin), Episil, MuGard, and Chemo Mouthpiece.
Oral Mucositis Market
The Oral Mucositis market size in the 7MM might grow at a CAGR of 6.6%.
The rising incidence of cancer cases, the expected approval and widespread adoption of emerging therapies such as Avasopasem, SGX942, BupiZenge, and others and an increase in R&D activities are expected to drive growth in the Oral Mucositis market size.
Oral Mucositis Emerging Therapies/Devices and Key Companies
Avasopasem (GC4419): Galera Therapeutics
SGX942: Soligenix
Validive (Clonidine Lauriad): Monopar Therapeutics
CareMin650: NeoMedLight
Cooral/CoolPrevent: BrainCool
MuReva Phototherapy System: MuReva (Lumitex)
BupiZenge: Oncozenge
For complete information on the emerging therapies, visit @ Oral Mucositis Treatment Drugs
Oral Mucositis Market Driver
Increasing Incidence of Cancer patients
Ongoing Research and Development
Robust Oral Mucositis Pipeline Activity
Oral Mucositis Market Barriers
Limited or No Awareness About the Disease
Lack of Diagnostic Methods
The High Cost of Treatment
Scope for the Report
Coverage: 7MM (the US, EU5 (the UK, Germany, Italy, Spain, and France) and Japan)
Study Period: 2018-30
Oral Mucositis Key Companies: Galera Therapeutics, Monopar Therapeutics, Soligenix, NeoMedLight, BrainCool, MuReva (Lumitex), Oncozenge, among others.
Oral Mucositis Key Pipeline Therapies/Devices: Avasopasem(GC4419), SGX942 , Validive (Clonidine Lauriad), CareMin650, Cooral/CoolPrevent, MuReva Phototherapy System, BupiZenge,and others.
Oral Mucositis Segmentation: By Geography, By Oral Mucositis therapies
Analysis: Comparative and conjoint analysis of Oral Mucositis emerging therapies/devices
Tools Used: SWOT Analysis
Case Studies
KOL’s Views
Analyst’s Views
Table of Contents
1.
Key Insights
2.
Executive Summary of Oral Mucositis
3.
SWOT Analysis of Oral Mucositis
4.
Oral Mucositis: Market Share (%) Distribution Overview at a Glance: By Country
5.
Oral Mucositis Epidemiology and Market Methodology
6.
Oral Mucositis: Disease Background and Overview
7.
Diagnosis of Oral Mucositis
8.
Oral Mucositis Epidemiology and Patient Population
9.
Oral Mucositis Epidemiology Scenario: 7MM
10.
Oral Mucositis The United States Epidemiology
11.
Oral Mucositis EU-5 Epidemiology
12.
Oral Mucositis Japan Epidemiology
13.
Current Treatment Practices: Oral Mucositis
14.
Prevention of Oral Mucositis
15.
Guidelines of Oral Mucositis
16.
Oral Mucositis Unmet Needs
17.
Patient Journey of Oral Mucositis
18.
Key Endpoints in Oral Mucositis Clinical Trials
19.
Oral Mucositis Marketed Therapies
20.
Oral Mucositis Emerging Therapies
21.
Oral Mucositis: Seven Major Market Analysis
22.
Oral Mucositis 7MM Market Size
23.
Oral Mucositis The United States Market Size
24.
Oral Mucositis EU-5 Market Size
25.
Oral Mucositis Japan Market Size
26.
Market Access and Reimbursement of Oral Mucositis Therapies
27.
Market Drivers of Oral Mucositis
28.
Market Barriers of Oral Mucositis
29.
Appendix
30.
DelveInsight Capabilities
31.
Disclaimer
32.
About DelveInsight
For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare, and Biotech Blog Posts
Related Reports
Stomatitis Pipeline Insights
Get a comprehensive analysis of Stomatitis pipeline therapies and key companies such as Galera Therapeutics, Otsuka Pharmaceuticals, Enzychem Lifesciences Corporation, Izun Pharma Ltd, Soligenix, Santalis Pharmaceuticals, Inc., Astellas Pharma, among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Sandeep JoshiEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: www.delveinsight.com/